Watson to become world’s 3rd largest #Generics Drug Maker with the #acquisition of Actavis

Watson Pharmaceuticals in a bid to increase their reach in the European and Asian markets, have spent $5.6 billion to buy Swiss drug maker Actavis. Watson is now placed just behind Novartis and Teva as the third biggest generic player in the industry. Watson has high hopes for the acquisition and expects a $8 billion revenue in 2012. "The transaction …